Neurotech International Limited (ASX: NTI) is a clinical-stage biopharmaceutical company focused on developing NTI-164, a multi-purpose oral cannabinoid therapy for paediatric neurological disorders.

With Phase III trials expected to conclude by year-end, we believe Neurotech is entering its most significant inflection point to date. A successful outcome would leave the company ideally positioned to execute an out-licensing agreement as the cornerstone of its commercialisation strategy, which we see as another key catalyst for a material re-rating. 

We continue to see strong investor appetite for companies executing successful out-licensing strategies. We believe NTI is well positioned to attract similar investor interest given a successful out-licensing agreement would not only provide external validation of its technology but demonstrate a pathway to commercialisation whilst reducing funding requirements and execution risk in its longer-term strategy.

Access the Full Desk Note

Key Highlights

• Clear Pathway to Commercialisation – Iterative dual approach with a licensing deal for U.S jurisdiction expected as part of its strategy. We expect Australian revenues and commercialisation to potentially be in late CY27 after Phase-III readout by CY26.

   

• Large Target Underserved Market Across a Diversified Pipeline. High-Value Precedent transactions for Selective Use-Cases – NTI-164 has a significant attainable global TAM, with multiple focus areas across Autism Spectrum Disorder (ASD), Rett Syndrome, Cerebral Palsy (CP), Paediatric Autoimmune Neuropsychiatric Disorders (PANDAS) and Paediatric Acute-onset Neuropsychiatric Syndrome (PANS). Phase II/III Neuro Diseases Transactions in the U.S from 2016-2025 have commanded Milestone Payments of up to US$1.9bn, and royalties of up to 12%. Deal Values across similar IP’s at Stage I/II level have commanded premiums in excess of US$270m in the U.S biotech market.

   

• Already Available for Public Use - NTI-164’s availability through Australia’s Authorised Prescriber (AP) Scheme provides Neurotech with a unique advantage, generating real-world clinical validation and evidence of strong patient demand ahead of potential commercialisation. This positions NTI among a rare cohort of biotechs with both clinical and real-world datasets, creating a meaningful data-driven moat and reinforcing the potential value of NTI-164. We see significant real-world evidence of NTI-164 already changing lives. To be reimbursed as part of pharmaceutical Benefit Scheme (PBS).

   

• Macro-Tailwinds and Strategic IP - Note that in the U.S, only 1 FDA-approved cannabidiol drug exists (Epidiolex, 2018). Following an Executive Order by the current U.S Administration (‘Increasing Medical Marijuana and Cannabidiol Research’) – we think that following Australian Phase III, there will be strong commercial and strategic value for NTI-164 to be licensed further (or acquired) for the U.S Market.

Access the Full Desk Note